Reuters logo
BRIEF-Iovance Biotherapeutics announces FDA fast track designation for LN-144 for treatment of advanced melanoma
2017年8月31日 / 晚上8点55分 / 19 天前

BRIEF-Iovance Biotherapeutics announces FDA fast track designation for LN-144 for treatment of advanced melanoma

Aug 31 (Reuters) - Iovance Biotherapeutics Inc

* Iovance Biotherapeutics announces FDA fast track designation for LN-144 for treatment of advanced melanoma Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below